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Abstract
Based on the extensive, poor, intermediate and ultrarapid
phenotypes of patients, inferences may be made relative to
drug metabolism, ultimately leading to changes in therapeutic drug choice or dosing. Phenoconversion is a phenomenon
that occurs when an individual's drug metabolizing capacity
is altered due to the combination of a drug-drug interaction
and a drug-gene interaction. Phenoconversion can affect
pharmacokinetics as well as pharmacodynamics. Some examples of phenoconversions include amiodarone-warfarin,
duloxetine-codeine, rifampin-clopidogrel, and rifampinwarfarin. Pharmacists must consider phenoconversion in
cases of multi-drug theraI>Y·
Introduction/Background
Pharmacogenomics (PGx), in relation to drug metabolism,
stems from the basics of the human genome itself. It begins
with the genotype (specific inherited alleles, forms of a gene),
which, along with other factors, leads to the phenotype
(expression of the individual gene via physical traits or
physiological functions). 1 Relative to the deoxyribonucleic
acid (DNA) code are polymorphisms, which are genetic mutations found in more than 1 percent of the population. Most
often these mutations are single base substitutions known as
single nucleotide polymorphisms (SNPs).1 With SNPs,
resulting variant genes and subsequent expressions are what
define an individual's inherent capabilities, such as those
related to drug metabolism. Based on the occurrence of SNPs
and other mutations, some individuals will have "normal"
protein function, while others may not.2 Some of the proteins
of interest function to metabolize drugs, therefore when
their function is altered or absent, two aspects of drug metabolism can change dramatically the extent of drug metabolism and the rate of drug metabolism. In general, a
"wild-type" allele (normal gene) will code for the typical or
normal enzyme, and an individual with this type of allele
would be considered an extensive (normal) metabolizer (EM;
NM) of drugs which are substrates for the enzyme. In contrast, individuals may receive variant alleles, which result in
metabolism phenotypes of poor (PM), intermediate (IM), or
ultrarapid (UM). Based on these phenotypes, inferences may
be made relative to drug metabolism, ultimately leading to
changes in therapeutic drug choice or dosing (e.g., choice of
antiplatelet medication or alteration of dose for a chemotherapeutic agent).2.3
Pharmacogenomics as explained above has had greater uptake in recent years, resulting in more proactive genetic testing occurring prior to drug administration in an attempt to
decrease or avoid adverse drug reactions that are linked to
variant alleles. However, while PGx is starting to be applied
in practice today, the problem of phenoconversion has presented itself as another piece of the puzzle. Phenoconversion
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is an alteration in an individual's drug metabolizing capacity
due to the combination of a drug-drug interaction and a
drug-gene interaction. In other words, an individual's phenotype is transformed as a consequence of a drug-drug-gene
interaction (DDGI) (e.g., an IM being converted to a PM). One
of the interactions, the drug-drug interaction, is familiar to
pharmacists since individuals are often put on multidrug
therapies that may lead to additive effects or possible toxicities either by synergistic or antagonistic mechanisms. The
drug-gene interaction component of phenoconversion is
described by the previously discussed definition of pharmacogenomics and different metabolic "intrinsic" (inherited)
phenotypes. 1 -3 The consequence of a DDGI is altered pharmacodynamics and/or pharmacokinetics. Pharmacodynamic
(PD) interactions occur when one drug alters the response to
another drug through alteration in drug receptors without
the influence of a change in drug concentration. Pharmacokinetic (P,K) interactions occur when a drug interferes with the
absorption, distribution, metabolism and/or excretion
(ADME) of another drug, here altering the concentration of
the original drug. 3 Either one of these situations can create
phenoconversion, but ultimately an individual's genotype
will no longer match their predicted phenotype. A DOG! occurs when the first drug is given to an individual with altered
drug metabolism due to a variant genotype (drug-gene interaction) followed by an additional drug that alters the PD or
PK of the first drug (drug-drug interaction). Now, instead of a
drug-gene interaction alone or a drug-drug interaction alone,
we must consider a DDGI, and this phenoconversion can result in increased or decreased drug concentrations with subsequent adverse effects or therapeutic failures, respectively.
The following are individual examples of phenoconversion.

Amiodarone and Warfarin
Warfarin is a frequently prescribed medication for anticoagulation therapy and is commonly given to patients that
have atrial fibrillation, a heart valve replacement or a history
of clotting for prevention of stroke and other sequelae.
Warfarin is manufactured as a racemic mixture, where SO
percent exists as the S-isomer and the remainder as the
R-isomer. The S-isomer, however, is almost five times more
potent than the R-isomer, resulting in this form's more extensive role in warfarin's therapeutic activity.1 As such, the
cytochrome P450 enzyme that is responsible for metabolizing warfarin's S-isomer, CYP2C9, plays a significant role in
determining the dose that will be required in a given
patientl,4 Those individuals with a *1/*1 genotype are considered to be more extensive in their ability to metabolize
warfarin. Individuals with some combination containing a
*2 or *3 allele (e.g., *1/*2, *2/*2, *2/*3, etc.) have reduced
enzyme activity, meaning that warfarin's clearance is decreased and warfarin will linger in the body for a longer time
as a result of a longer half-life. A decrease in the clearance of

THE PHARMACY AND WELLNESS REVIEW

39

PharDiacogenomics ..............................P.he•n•o•c•on•v•e•rs•i•on•:•D•r•ug.-.D.ru•g•-•Ge•n•e•I•n•te•r•ac•a•·o.n.s. . . . . . . . . . . . . . . . . . . . . .__
warfarin of approximately 30 to 40 percent can be expected
when an individual has a *2 allele, with an individual who is
homozygotic (*2/*2) having a greater decrease in clearance
as compared to the heterozygotic individual (*1/*2). The
effects of CYP2C9 allele variation on the clearance of warfarin is even more pronounced in individuals with a *3 allele,
where a homozygotic individual may have a decreased clearance approaching 80 to 90 percent. The *2 and *3 alleles are
most frequently found in those of European descent. These
phenotypes are not categorized in the typical manner as extensive metabolizers, intermediate metabolizers, or poor
metabolizers, but instead can be thought of as existing on a
continuum. In this manner, a *lf*l genotype would be
comparable to an extensive metabolizer with efficient metabolism and a *3/*3 individual would resemble a poor metabolizer. Other alleles associated with decreased enzyme
activity include CYP2C9*5, *6, *8, and *11, which are found
most commonly in the African American population. 4 When
another drug that utilizes this CYP is prescribed for a patient
that is already taking warfarin, there is a potential for decreasing the enzyme's ability to metabolize warfarin, thereby
resulting in a need to adjust the dose accordingly (Table 1).
In order to ensure that a patient is receiving the correct dose
of warfarin for their phenotype, that patient's JNR. or international normalized ratio, is monitored closely. When measuring an INR, a small collection of blood is analyzed in order
to determine the amount of time it takes for that patient's
blood to clot. A typical healthy individual that is not taking
warfarin could expect an JNR value of approximately l, while
those consuming warfarin would have higher INR values.
When a patient has suffered from or is at risk of developing a
clot, it is necessary to keep the INR value between 2 and 3. In
individuals that have had a mechanical heart valve placed, an
INR between 2.5 and 3.5 is desired. The JNR must be moni-

tared by a health care professional regularly, as many medications, foods and drinks can impact the anticoagulant effects
exhibited by warfarin.s
For example, ML is an 80-year-old woman who has been taking warfarin for four years after she developed a deep vein
thrombosis. Her INR has remained steady at 2.7 while on her
prescribed dose of 3 mg daily throughout those years of use.
Her genotype is CYP2C9*2/*3, indicating that she has
decreased warfarin metabolism, thus defining a drug-gene
interaction. Here, ML has a 60 percent decrease in the clearance of warfarin when compared to the normal wild-type,
*1/*1 genotype.1 While not specifically defined for CYP2C9,
ML may generally be considered an intermediate metabolizer on the continuum from *1/*1 to *3/*3. Recently, ML
was hospitalized to treat a ventricular arrhythmia. During
this time, she was started on amiodarone.
Amiodarone also utilizes the CYP2C9 enzyme and is known
to be a moderate inhibitor of this enzyme. This causes a reduction in warfarin clearance by 50 to 80 percent.6 Enzyme
inhibition is primarily caused by the metabolite, desethylamiodarone, which is a much more potent inhibitor of CYP2C9
than the parent amiodarone form. Furthermore, it has been
demonstrated that the degree to which CYP2C9 is inhibited is
related to the amiodarone dose that is administered.4Therefore, patients taking higher doses of amiodarone would experience a greater decrease in CYP2C9 function and would
resultantly require a lower dose ofwarfarin.
In the case involving ML, phenoconversion would effectively
move ML along the continuum from resembling an intermediate metabolizer to resembling a poor metabolizer.1 Consequently, ML would have higher concentrations of warfarin in
her body, thus potentiating the anticoagulant effects of her

Table 1. The CYP2C9 "warfarin dosing continuu01." The *2 and *3 variant alleles i01part decreased warfarin 01etabolism (clearance), necessitating decreased warfarin 01aintenance doses. 4

VKORCl

GGb

CYP2C<J'

*l/* 1

* 1/*2

*l/*3

*2/*2

*2/*3

*3/*3

5-7 mg

5-7 mg

3-4 mg

3-4mg

3-4mg

0.5-2 mg

a *1

- normal CYP2C9 activity; *2 - somewhat decreased CYP2C9 activity; *3 - greatly decreased
CYP2C9 activity.
b The common VKORCl genotype, imparting "normal" warfarin pharmacodynamics.
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medication, as can be verified through an increase in her
typically stable INR from 2.7 to 5.3. This places ML at an increased risk for bleeding.4,7,8
The original drug-gene interaction is a component of the
overall interaction with the addition of amiodarone. Due to
the decreased warfarin metabolism rate as a result of the
DDGI, it is recommended that on the third or fourth day following amiodarone's inclusion in the patient's medication
regimen, the usual warfarin dose should be decreased by
one-third to one-half. In ML's situation, that means that the
dose should be decreased from 3 mg daily to 1.5 to 2 mg
daily. Her INR should be monitored closely during this time
until stabilized.B
Duloxetine and Codeine
SK, an African American woman, brings a prescription for
acetaminophen 300 mg/codeine phosphate 30 mg to the
pharmacy because she has been having severe back pain for
the past three days. Previously, as part of a pharmacy program emphasizing personalized medicine, SK provided a
DNA sample via a cheek swab. The laboratory working with
the pharmacy tested for many different genes related to drug
metabolism; this included the gene coding for the drug metabolizing enzyme CYP2D6, for which SK had the genotype of
CYP2D6*4/*17, indicating that SK is an intermediate metabolizer. From this genetic test, it is determined that SK may not
effectively metabolize codeine to its active metabolite, morphine.9 The doctor writes the acetaminophen 300 mg/
codeine phosphate 30 mg prescription for one tablet every
four hours as needed.10 When checking the prescription, the
pharmacist discovers that SK is also prescribed duloxetine
for her depression. This is a potential drug-drug-gene interaction because duioxetine is a moderate inhibitor of CYP2D6
and could therefore affect the metabolism of codeine, which
can result in inadequate pain relief for SK.6

The phenotype of the patient for the CYP2D6 gene is determined through an activity score, which is calculated by adding the scores of the two alleles of the individual's genotype.
The alleles *1, *2, *27, *33, *45, *46, *39, *48, and *53 have
normal activity and are given a score of 1. Reduced function
alleles include *9, *10, *17, *29, *41, *50, *54, *55, *59, *69,
and *72; these alleles have an activity score of 0.5. All other,
currently identified alleles are considered non-functional and
have an activity score of 0.9 Ultrarapid metabolizers of codeine have an activity score over 2, which can occur when
there are more than two functional alleles present, as some
individuals have two or more copies of the gene. Normal metabolizers have an activity score between 1 and 2, intermediate metabolizers have a score of 0.5, and poor metabolizers
have a score of 0.10 Table 2 summarizes these activity scores
and the metabolizing function of various alleles of CYP2D6.
SK would have an activity score of 0.5, receiving a score of 0
from the *4 allele and 0.5 from the *17 allele; her phenotype
would therefore be an intermediate metabolizer.
As a moderate inhibitor of CYP2D6, duloxetine could prevent
codeine from being metabolized to morphine and prevent it
from having a therapeutic effect. A moderate inhibitor of a
CYP enzyme is defined as causing a twofold or more increase
but less than fivefold increase in area under the curve (AUC)
of the enzyme's substrate.6 In the case of SK, the duloxetine
could inhibit the CYP2D6 enzyme, a product of the *17 allele,
which already has reduced activity; this would inhibit codeine conversion to morphine, eliminating most of the analgesic effect provided by the medication. SK would undergo a
phenoconversion from an intermediate metabolizer of codeine to a poor metabolizer if she were to take duloxetine
and codeine concomitantly. For instance, her metabolism of
codeine may be considered similar to someone with the
CYP2D6*4/*4 genotype, resulting in little or no therapeutic
benefit because the drug is not metabolized to its active metabolite (codeine). 9

Table 2. Examples of CYP2D6 Variants.a

Function

Example Alleles
(Activity score)b

Normal

*le, *2, *27, *33, *35, others
(1)

Decreased

*17, *29, *41, *49, *50, others
(0.5)

Lost

*3, *4, *5, *6, *7, others (0)

a Adapted

by permission from Macmillan Publisher Ltd: Clinical Pharmacology & Therapeutics 2012;91(2):3216, Crew et al., copyright 2012.
hThe activity score relates formation of metabolite to an individual's genetics, with those producing more metabolite being assigned a higher activity score.
c Designated as the "wild-type," and the most frequently occurring form with normal function.
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If codeine is going to be used in patients taking drugs that
moderately inhibit the CYP2D6 enzymes such as duloxetine,
the patient should be carefully monitored to determine
whether or not pain relief is adequate. There are also alternative therapy options for pain management that do not involve the CYP2D6 metabolism pathway and therefore would
avoid phenoconversion due to concomitant therapy of
codeine with duloxetine. Fentanyl, oxymorphone, hydromorphone and morphine are among the analgesics not metabolized by CYP2D6. Tramadol, hydrocodone and oxycodone
should be avoided because they are also metabolized by
CYP2D6 to their active forms and could potentially be affected by the inhibitory effects of duloxetine. In addition,
there are non-opioid based pain medications such as NSA!Ds
and acetaminophen that do not require CYP206 for activation or metabolism. The choice of alternative therapy should
be made based on pain severity relative to each individuaJ.9
In the case of SK, the pharmacist called the prescriber, who
agreed to switch the prescription from acetaminophen 300
mg/codeine phosphate 30 mg to a non-opiate alternative.
Rifampin and Clopidogrel
Clopidogrel is an antiplatelet prodrug whose activation is
known to be dependent upon the CYP2C19 phenotype of the
given individual. For CYP2C19, there are several variant
alleles that will dictate the patient's capacity for prodrug activation (metabolism) to the active metabolite. The most
common form of the CYP2C19 gene, *1, is considered the wild
-type, or normal allele, and designates extensive (normal)
metabolism. Therefore, an individual that is homozygous
(*1/*1) would exhibit extensive metabolism of the clopidogrel prodrug into its active form. Loss of enzyme function is
observed in the *2, *3, *4, *5, *6, *7, and *8 variant alleles. Of
those individuals that possess a CYP2C19 loss-of-function
allele, approximately 90 percent possess the *2 allele, making it the most common variant form. When paired with the
wild-type *1 in a heterozygous individual (e.g., *1/*2), the
patient will be an intermediate metabolizer of clopidogrel.
Homozygous individuals with decreased function alleles (e.g.,
*2/*2) are considered poor metabolizers. Additionally, there
is one known variant allele that is associated with increased
metabolic function, the *17 allele. Individuals that are heterozygous (*1/*17) or are homozygous for the *17 allele are
considered ultrarapid metabolizers of clopidogreJ.1,6 It is vital
that a patient's phenotype is determined prior to clopidogrel
therapy, as this will determine the possibility of therapeutic
success that the patient may experience. Typically, with antiplatelet therapy for coronary artery stent placement, if a patient is found to be an intermediate or poor metabolizer,
other therapies should be considered due to the lack of complete conversion of the prodrug to its active form and the
increased risk of adverse cardiovascular events noted in such
patients.11
JM is a 49-year-old man who has enjoyed smoking a pack of
cigarettes daily for the past 40 years. He has a maternal family history of hypertension and hyperlipidemia. Recently, JM
suffered a myocardial infarction while working at his job as a
prison guard. During heart catheterization, a stent was
placed in two of JM's coronary arteries. JM was started on
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clopidogrel 75 mg daily. At the time JM started clopidogrel, a
blood sample was sent for CYP2C19 genotyping. The lab reports JM's genotype to be CYP2C19*1/*2, thus illustrating the
drug-gene interaction. His physician, not being familiar with
the genotyping data, increases the clopidogrel dose to 150
mg daily. Several months later, while attending an annual
checkup required for all prison employees, JM received a
positive tuberculin skin test result. After additional blood
and sputum tests were conducted, it was determined that JM
had latent tuberculosis, and was placed on rifampin 600 mg
therapy for four months.
Rifampin is a known inducer of the CYP2C19 enzyme, and
consequently causes a twentyfold increase in the metabolizing capabilities of this enzyme.6 Therefore, when rifampin
and clopidogrel are used concomitantly, the amount of prodrug that is converted to the active metabolite within the body
vastly increases for the duration of the dual medication usage. Although JM's genotype remains CYP2C19*1/*2, thus
reflecting an intermediate metabolizer, his phenotype may
now more closely resemble that of a *1/*1 extensive metabolizer. With the increased dose of clopidogrel 150 mg daily
being employed, and the increased metabolism of clopidogrel
to its active form, higher concentrations of therapeutic metabolite will be found in JM's body. This puts JM at an increased risk of adverse drug events, including bleeding. In
reality, as JM is inherently a *1/*2, intermediate metabolizer,
he should receive an alternative antiplatelet drug. In this scenario, however, the physician chose to increase the dose of
clopidogrel. The addition of rifampin to treat JM completes
the drug-drug-gene interaction and the likely phenoconversion of JM from an intermediate to extensive metabolizer,
albeit, during rifampin therapy.
Rifampin and Warfarin
The previous example addresses a DDGI relative to a
prodrug. The following example addresses a DDGI relative to
an active drug, here, warfarin.
NF, a 62-year-old African American male, is admitted to the
hospital with chest pain and shortness of breath. He had a
positive purified protein derivative (PPD) tuberculin skin
test two months ago and, after a chest x-ray, was diagnosed
with latent tuberculosis (TB); he currently takes rifampin
600 mg daily. Another chest x-ray shows that his TB had not
become active, and the doctor orders a ventilation perfusion
scan, which shows that the blood flow in NF's lung is low
compared to the air in his lungs. The doctor suspects NF has
a pulmonary embolism (PE) and orders fondaparinux
sodium injections in order to treat the PE. NF is started on
warfarin concomitantly with the intent of using warfarin for
anticoagulation therapy beyond the hospital stay. The electronic medical record system allows access to NF's genetic
testing results to be retrieved from a secure database. The
data indicate that NF has a CYP2C9*2/*3 genotype, and has
the common genotype of vitamin K epoxide reductase
complex subunit 1 (VKORCl), which is also involved in the
response to warfarin. Utilizing the package label pharmacogenomic-based dosing chart, NF is started on 3 mg of warfarin daily.4.lo
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Rifampin is a moderate inducer of the CYP2C9 metabolizing
enzyme and thus causes a 50 to 80 percent decrease in the
AUC for drugs metabolized by CYP2C9, such as warfarin.6
The induction of CYP2C9 increases warfarin metabolism,
increasing its clearance and shortening the warfarin half-life.
This can result in decreased anticoagulation effect putting
the individual at risk of clot formation; sub-therapeutic warfarin concentrations can result in clot formation that can
have fatal consequences for the patient. Based solely on his
genotype of CYP2C9*2/*3 resulting in a poor metabolizer-like
phenotype, the daily warfarin dose of 3 mg would be considered appropriate. However, NF has latent TB and is taking
rifampin. The use of rifampin has resulted in a phenoconversion in NF as it has caused an increase in the metabolism of
warfarin, resulting in a clearance similar to that of an individual with a CYP2C9*1/*1 genotype, or that of a normal metabolizer. The 3 mg dose of warfarin would probably not be
sufficient in preventing blood clots in a normal metabolizer
and is thus not sufficient for NF while the rifampin is increasing his metabolism of warfarin. The dose of warfarin must be
guided by monitoring his INR and working to get the value
into the therapeutic range.
The pharmacist in the hospital realizes that there is a drugdrug-gene interaction when verifying the warfarin order and
calls the doctor in order to prevent NF from being readmitted to the hospital in the future with another blood clot. Warfarin could still be given to NF, but he would require a higher
dose (5-7 mg) in order for it to be effective.4 NF's INR is
monitored during his hospital stay, and the warfarin dose
increased until his INR is at a therapeutic level.
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When NF finishes his course of rifampin therapy in two
months, the higher dose of warfarin given previously will no
longer be required. Warfarin metabolism will no longer be
induced, as the rifampin will no longer be "on board." NF's
warfarin dose needs to be decreased because his genotype
suggests decreased metabolism as compared to a *1/*1 normal metabolizer. On the current dose and with relatively decreased metabolism, the concentration of warfarin will increase, putting NF at an increased risk for bleeding as noted
by a likely supratherapeutic INR. 4 NF's INR should be closely
monitored while the dose is being decreased in order to ensure he receives the correct dose.
Conclusion - What this Means for Pharmacists
The above examples depict some of the more distinct cases of
phenoconversion that are already evident in practice today.
They included both those which led to an increase in function
of metabolic proteins and a decrease in function of metabolic
proteins, but both were based on allelic differences in genetic
make-up relative to concomitant drug use, or a DDGI. Therefore, phenoconversion should be considered within clinical
judgment in cases of multi-drug therapy, and knowledge of
drug-drug and drug-gene interactions is necessary to optimize therapeutic effects while minimizing or avoiding adverse drug events.
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